After a 3-month pursuit, GlaxoSmithKline (GSK) has negotiated a deal on friendly terms to acquire its long-time partner Human Genome Sciences (HGS) for approximately US$3 B net of cash and debt. With the acquisition, GSK will gain full rights to the lupus drug Benlysta® (belimumab) and to albiglutide and darapladib, which are in late-stage development for type 2 diabetes and chronic coronary heart disease, respectively. HGS rejected GSK’s initial offer of US$2.6 B in April 2012 and initiated an auction process to find another buyer. However, after a white knight failed to emerge, the company was forced to negotiate a deal with GSK to avoid a share price collapse.